Valneva Austria GmbH
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
- Conditions
- ZikaZika Virus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT06334393
- Locations
- 🇺🇸
Flourish Research, Chicago, Illinois, United States
🇺🇸Velocity Clinical Research, Omaha, Nebraska, United States
🇺🇸Flourish Research, Chicago, Illinois, United States
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: ControlBiological: VLA1553 full doseBiological: VLA1553 half dose
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 304
- Registration Number
- NCT06106581
- Locations
- 🇭🇳
Inversiones en Investigacion Medica INVERIME, Tegucigalpa, Honduras
🇩🇴Fundacion Dominicana de Perinatologia Fundacion Probebe, Santo Domingo, Gazcue, Dominican Republic
🇩🇴Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP, Santo Domingo, Dominican Republic
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT06028841
- Locations
- 🇵🇦
Cevaxin, Centro de Vacunacion e Investigacion Internacional, Paitilla, Panama
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: VLA2001
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 178
- Registration Number
- NCT05364242
- Locations
- 🇳🇱
General Practitioners Research Institute (GPRI), Groningen, Netherlands
🇳🇱European Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht, Netherlands
🇳🇿Middlemore Clinical Trials, Auckland, Papatoetoe, New Zealand
COVID-19 Paediatric VLA2001-321 Study
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: VLA2001Drug: Active Comparator
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Valneva Austria GmbH
- Registration Number
- NCT05298644
Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years
- Conditions
- SARS-CoV-2 Virus Infection
- Interventions
- Biological: VLA2001
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 306
- Registration Number
- NCT04956224
- Locations
- 🇳🇿
Lakeland Clinical Trials Culloden, Papamoa, Papamoa Beach, New Zealand
🇳🇿Lakeland Clinical Trials Waikato, Hamilton, Nawton, New Zealand
🇳🇿Southern Clinical Trials Totara, Auckland, New Lynn, New Zealand
COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222
- Conditions
- SARS-CoV-2 Virus Infection
- Interventions
- Biological: VLA2001Biological: PlaceboBiological: AZD1222Biological: VLA2001 - adolescent part
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 4034
- Registration Number
- NCT04864561
- Locations
- 🇬🇧
Barnsley Hospital NHS FT, Barnsley, United Kingdom
🇬🇧North Bristol NHS Trust, Bristol, United Kingdom
🇬🇧Cambridge Biomedical Research Centre, Cambridge, United Kingdom
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: VLA1553
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 363
- Registration Number
- NCT04838444
- Locations
- 🇺🇸
Meridian Clinical Research, Grand Island, Nebraska, United States
🇺🇸Platinum Research Network, Omaha, Nebraska, United States
🇺🇸Accelerated Enrollment Solutions (AES), Chicago, Illinois, United States
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: Biological Vaccine VLA1553
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 409
- Registration Number
- NCT04786444
- Locations
- 🇺🇸
Dynamed Clinical Research, Tomball, Texas, United States
🇺🇸AMR Lexington, Lexington, Kentucky, United States
🇺🇸AMR Miami, Coral Gables, Florida, United States
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
- Conditions
- SARS-CoV-2 Virus Infection
- Interventions
- Biological: VLA2001
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 153
- Registration Number
- NCT04671017
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧University Hospital Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Southampton NIHR Clinical Research Facility, Southampton, United Kingdom